Distinguishing visceral leishmaniasis from intolerance to pegylated interferon-alpha in a thalassemic splenectomized patient treated for chronic hepatitis C

Am J Trop Med Hyg. 2008 Jul;79(1):9-11.

Abstract

A 37-year-old splenectomized man affected by beta-thalassemia and chronic hepatitis, recently treated with pegylated interferon-alpha (Peg-IFN), was admitted because of elevated fever lasting 3 months and unresponsiveness to broad-spectrum antibiotics. Laboratory studies showed white blood cell and platelet counts within the normal range but lower than observed before Peg-IFN treatment and an elevated erythrocyte sedimentation rate. The blood transfusion rate was reported to be increased compared with the period preceding Peg-IFN treatment. A diagnosis of visceral leishmaniasis (VL) was made after Leishmania amastigotes were identified from Giemsa-stained smears of bone marrow aspirates. Cure occurred after liposomal amphotericin B was administered. Symptoms of VL may be difficult to distinguish from the manifestations of Peg-IFN intolerance. We suggest that VL must be suspected in any immunodepressed patient with an unexplained fever and a history of exposure in an endemic area.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Amphotericin B / administration & dosage
  • Amphotericin B / pharmacology*
  • Amphotericin B / therapeutic use
  • Animals
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Leishmania / drug effects
  • Leishmaniasis, Visceral / diagnosis*
  • Leishmaniasis, Visceral / drug therapy
  • Male
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / therapeutic use*
  • Recombinant Proteins
  • Splenectomy
  • beta-Thalassemia / complications*
  • beta-Thalassemia / immunology

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • liposomal amphotericin B
  • Polyethylene Glycols
  • Amphotericin B
  • peginterferon alfa-2a